Posted by Michael Wonder on 18 Dec 2021
Tepmetko (tepotinib) receives positive CHMP opinion for patients with advanced NSCLC with METex14 skipping alterations
17 December 2021 - Tepmetko is the first and only oral MET inhibitor to receive CHMP positive opinion in Europe for adult patients with advanced NSCLC harboring alterations leading to METex14 skipping.
Merck, a leading science and technology company, today announced that the CHMP of the EMA adopted a positive opinion recommending approval of once daily oral Tepmetko (tepotinib) as monotherapy for the treatment of adult patients with advanced non-small cell lung cancer harbouring alterations leading to mesenchymal-epithelial transition factor gene exon 14 skipping, who require systemic therapy following prior treatment with immunotherapy and/or platinum-based chemotherapy.
